Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 819-825

  Jeon, Ye Won ^a   Suh, Young Jin ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Akt phosphorylation; Apoptosis; Breast cancer; Celecoxib; Luteolin; MCF 7; MDA MB 231

Indexed keywords

CELECOXIB; LUTEOLIN; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANTIOXIDANTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; LUTEOLIN; MCF-7 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SULFONAMIDES;

EID: 84872784215     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2158     Document Type: Article

References (31)

1. Glass AG, Carreon JD, Lacey JV Jr and Hoover RN: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99: 1152-1161, 2007. (Pubitemid 47233065)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643-658, 2004. (Pubitemid 40065543)
4. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95: 142-153, 2003. (Pubitemid 36193263)
5. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
6. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004. (Pubitemid 39100473)
7. Peto R, Boreham J, Clarke M, Davies C and Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822, 2000. (Pubitemid 30265099)
8. Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90: 423-429, 2004. (Pubitemid 38250640)
9. Crawford YG, Gauthier ML, Joubel A, Mantei K, Kozakiewicz K, Afshari CA and Tlsty TD: Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 5: 263-273, 2004. (Pubitemid 38402118)
10. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2: 632-642, 2004. (Pubitemid 39557666)
11. Kulp SK, Yang YT, Hung CC, et al: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64: 1444-1451, 2004. (Pubitemid 38235615)
12. Brasky TM, Bonner MR, Moysich KB, et al: Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21: 1503-1512, 2010.
13. Birt DF, Hendrich S and Wang W: Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90: 157-177, 2001. (Pubitemid 32913477)
14. Lin Y, Shen HM, Shi R and Wang X: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8: 634-646, 2008.
15. Suh YJ, Chada S, McKenzie T, Liu Y, Swisher SG, Lucci A and Hunt KK: Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Surgery 138: 422-430, 2005. (Pubitemid 41415568)
16. Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj BA and Mukherjee P: A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res 8: R69, 2006.
17. Chiang CT, Way TD and Lin JK: Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol Cancer Ther 6: 2127-2138, 2007.
18. Shih YL, Liu HC, Chen CS, et al: Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors. J Agric Food Chem 58: 235-241, 2010.
19. Ghosh N, Chaki R, Mandal V and Mandal SC: COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62: 233-244, 2010.
20. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN and Beauchamp RD: Transforming growth factor beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 275: 6628-6635, 2000. (Pubitemid 30129965)
21. Sheng H, Williams CS, Shao J, Liang P, DuBois RN and Beauchamp RD: Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 273: 22120-22127, 1998. (Pubitemid 28405396)
22. Sheng H, Shao J and Dubois RN: K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 61: 2670-2675, 2001. (Pubitemid 32691132)
23. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P and Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide- dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277: 27613-27621, 2002. (Pubitemid 34966703)
24. Browning AM, Walle UK and Walle T: Flavonoid glycosides inhibit oral cancer cell proliferation - role of cellular uptake and hydrolysis to the aglycones. J Pharm Pharmacol 57: 1037-1042, 2005.
25. Ciolino HP, Wang TT and Yeh GC: Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res 58: 2754-2760, 1998. (Pubitemid 28311904)
26. Doostdar H, Burke MD and Mayer RT: Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144: 31-38, 2000. (Pubitemid 30201617)
27. Lee LT, Huang Y T, Hwang JJ, et al: Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res 22: 1615-1627, 2002.
28. Fang J, Zhou Q, Shi XL and Jiang BH: Luteolin inhibits insulinlike growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 28: 713-723, 2007. (Pubitemid 46523369)
29. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with Celecoxib in a clinical trial for Colorectal Adenoma Prevention. N Eng J Med 352: 1071-1080, 2005. (Pubitemid 40365348)
30. Horinaka M, Yoshida T, Shiraishi T, et al: Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 24: 7180-7189, 2005. (Pubitemid 41679280)
31. Chen D, Chen MS, Cui QC, Yang H and Dou QP: Structure-proteasome- inhibitory activity relationships of dietary flavonoids in human cancer cells. Front Biosci 12: 1935-1945, 2007. (Pubitemid 46846817)